AOD-9604 Research Monograph: Overview and Applications

Discovery & Origin

AOD-9604 represents a synthetic peptide fragment derived from the C-terminal region of human growth hormone, specifically encompassing amino acids 176-191 [2]. This 16-amino acid sequence was identified and developed as part of research efforts to isolate the lipolytic properties of growth hormone while eliminating its growth-promoting and diabetogenic effects [4].

Mechanism of Action

The primary mechanism of AOD-9604 involves selective activation of lipolytic pathways in adipose tissue without stimulating overall growth hormone receptor signaling [2]. The peptide demonstrates ability to enhance fat oxidation and inhibit lipogenesis through specific interactions with adipocyte cellular machinery. Unlike full-length growth hormone, AOD-9604 does not significantly affect glucose metabolism or insulin sensitivity, making it a potentially safer alternative for metabolic applications [4].

Clinical Applications & Research

Research into AOD-9604 has focused primarily on metabolic disorders and weight management applications. The peptide has been investigated for its potential in treating obesity and related metabolic conditions through its selective fat-burning properties [4]. More recently, attention has shifted toward orthopedic and sports medicine applications, where AOD-9604 is being evaluated for potential benefits in musculoskeletal injury recovery and athletic performance enhancement [3].

Studies in therapeutic peptides for orthopedic applications have highlighted AOD-9604 among compounds showing promise for tissue repair and recovery acceleration [5]. However, comprehensive clinical trials demonstrating definitive efficacy in these applications remain limited.

Safety Profile & Regulatory Status

Safety assessments of AOD-9604 have generally indicated a favorable toxicological profile compared to full-length growth hormone, primarily due to its lack of growth-promoting effects [6]. The peptide does not interfere with standard growth hormone immunoassays used in anti-doping protocols, which has been specifically documented in analytical studies [1].

Despite its research history, AOD-9604 remains unapproved for therapeutic use in any major regulatory jurisdiction. Current applications are limited to research settings and investigational protocols.

Future Directions

Ongoing research continues to explore the therapeutic potential of AOD-9604 in musculoskeletal medicine and metabolic disorders. Future studies will likely focus on establishing definitive clinical efficacy through properly controlled trials and determining optimal dosing regimens for specific therapeutic applications [3][5].

The development of improved formulation strategies and delivery methods may enhance the clinical utility of AOD-9604, particularly for applications requiring sustained tissue exposure or targeted delivery to specific anatomical sites.

AOD-9604 is a synthetic peptide fragment derived from the C-terminal region of human growth hormone (hGH), specifically encompassing amino acids 176-191. This 16-amino acid peptide was developed as a potential anti-obesity therapeutic agent, designed to retain the lipolytic properties of growth hormone while eliminating its growth-promoting effects. The peptide demonstrates selective fat-burning activity through mechanisms involving enhanced lipolysis and inhibition of lipogenesis in adipose tissue.

Preclinical studies have shown that AOD-9604 can stimulate fat metabolism without affecting blood glucose levels or insulin sensitivity, distinguishing it from full-length growth hormone. The compound has been investigated for its potential applications in metabolic disorders and weight management, though clinical development has been limited. Research indicates that AOD-9604 may work through specific cellular pathways related to adipocyte metabolism and energy expenditure.

The peptide has gained attention in sports medicine and orthopedic applications, where it is being evaluated for potential benefits in musculoskeletal injury recovery and athletic performance enhancement. However, comprehensive clinical trials demonstrating efficacy and safety in humans remain limited, and the peptide is not approved for therapeutic use in any jurisdiction.

• Development Status: Research Only

Synonyms: Anti-Obesity Drug 9604, AOD9604

Trade Names: Metabolic

Category: peptide, growth_hormone_fragment, metabolic_modulator

Origin: synthetic

Quick Reference

• Routes: subcutaneous, intramuscular
• Typical Doses: 0.25-1.0 mg daily
• Half-Life: 2-4 hours
• Stability: Refrigerated storage required
• Main Targets: growth_hormone_receptors, adipocyte_receptors

Regulatory Notes

AOD-9604 remains an investigational peptide without regulatory approval for human therapeutic use. Studies have confirmed that it does not interfere with standard growth hormone immunoassays used in anti-doping protocols.